Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Immunotherapy Biomarkers

Section edited by Lisa H. Butterfield, PhD

Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.

Previous Page Page 1 of 2 Next Page
  1. Content type: Research article

    It remains challenging to characterize the functional attributes of chimeric antigen receptor (CAR)-engineered T cell product targeting CD19 related to potency and immunotoxicity ex vivo, despite promising in ...

    Authors: Qiong Xue, Emily Bettini, Patrick Paczkowski, Colin Ng, Alaina Kaiser, Timothy McConnell, Olja Kodrasi, Máire F. Quigley, James Heath, Rong Fan, Sean Mackay, Mark E. Dudley, Sadik H. Kassim and Jing Zhou

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:85

    Published on:

  2. Content type: Research article

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...

    Authors: Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:81

    Published on:

  3. Content type: Research article

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...

    Authors: Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:82

    Published on:

  4. Content type: Research article

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...

    Authors: Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:67

    Published on:

  5. Content type: Research article

    Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to ident...

    Authors: Laura E. Johnson, Brian M. Olson and Douglas G. McNeel

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:56

    Published on:

  6. Content type: Research article

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...

    Authors: Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:33

    Published on:

  7. Content type: Meeting report

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...

    Authors: James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:29

    Published on:

  8. Content type: Research article

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...

    Authors: James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:25

    Published on:

  9. Content type: Research article

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...

    Authors: Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:18

    Published on:

  10. Content type: Research article

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...

    Authors: Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:20

    Published on:

  11. Content type: Research article

    Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...

    Authors: Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez and Constantin N. Baxevanis

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:75

    Published on:

  12. Content type: Review

    Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibi...

    Authors: Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield and Magdalena Thurin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:76

    Published on:

  13. Content type: Review

    There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical...

    Authors: Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield and Magdalena Thurin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:77

    Published on:

  14. Content type: Research article

    Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, a...

    Authors: Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Mariano Severgnini, F. Stephen Hodi, Robert I. Haddad, Roy B. Tishler and Jonathan D. Schoenfeld

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:32

    Published on:

  15. Content type: Research article

    Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior ...

    Authors: Jason J. Luke, Yuanyuan Zha, Karen Matijevich and Thomas F. Gajewski

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:35

    Published on:

Previous Page Page 1 of 2 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement